Total Payments
$112,568
2024 Payments
$11,033
Companies
17
Transactions
100
Medicare Patients
1,016
Medicare Billing
$208,387
Payment Breakdown by Category
Consulting$95,663 (85.0%)
Other$8,117 (7.2%)
Research$4,129 (3.7%)
Education$2,500 (2.2%)
Travel$1,118 (1.0%)
Food & Beverage$1,039 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $95,663 | 59 | 85.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7,117 | 7 | 6.3% |
| Unspecified | $4,129 | 7 | 3.7% |
| Education | $2,500 | 1 | 2.2% |
| Travel and Lodging | $1,118 | 7 | 1.0% |
| Food and Beverage | $1,039 | 18 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000 | 1 | 0.9% |
Payments by Type
General
$108,438
93 transactions
Research
$4,129
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $35,703 | 27 | $0 (2023) |
| Boehringer Ingelheim Finland Ky | $21,750 | 30 | $0 (2018) |
| Daiichi Sankyo Inc. | $14,815 | 8 | $0 (2024) |
| AstraZeneca UK Limited | $7,772 | 6 | $0 (2024) |
| PFIZER INC. | $6,540 | 5 | $0 (2019) |
| Merck Sharp & Dohme LLC | $5,728 | 4 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $5,626 | 7 | $0 (2024) |
| EMD Serono, Inc. | $2,760 | 1 | $0 (2020) |
| Regeneron Pharmaceuticals, Inc. | $2,718 | 3 | $0 (2022) |
| GENZYME CORPORATION | $2,524 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,033 | 7 | AstraZeneca UK Limited ($7,670) |
| 2023 | $10,893 | 14 | Merck Sharp & Dohme LLC ($5,728) |
| 2022 | $12,668 | 7 | Daiichi Sankyo Inc. ($4,726) |
| 2021 | $14,868 | 9 | Novartis Pharmaceuticals Corporation ($5,263) |
| 2020 | $13,574 | 7 | Novartis Pharmaceuticals Corporation ($7,014) |
| 2019 | $22,049 | 16 | Novartis Pharmaceuticals Corporation ($17,449) |
| 2018 | $12,313 | 19 | Boehringer Ingelheim Finland Ky ($7,250) |
| 2017 | $15,170 | 21 | Boehringer Ingelheim Finland Ky ($14,500) |
All Payment Transactions
100 individual payment records from CMS Open Payments — Page 2 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/24/2022 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,620.00 | General |
| 04/15/2022 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2022 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,226.25 | General |
| 11/18/2021 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 10/28/2021 | Ipsen Biopharmaceuticals, Inc | ONIVYDE (Drug) | Education | Cash or cash equivalent | $2,500.00 | General |
| Category: Oncology | ||||||
| 08/31/2021 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: ONCOLOGY | ||||||
| 08/10/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| 07/01/2021 | Novartis Pharmaceuticals Corporation | ILARIS (Biological) | Consulting Fee | Cash or cash equivalent | $4,062.50 | General |
| Category: IMMUNOLOGY | ||||||
| 05/17/2021 | Novartis Pharmaceuticals Corporation | — | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $1,000.00 | General |
| 02/25/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,562.50 | General |
| 02/25/2021 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $937.50 | General |
| 01/25/2021 | Novartis Pharma AG | TABRECTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: ONCOLOGY | ||||||
| 12/15/2020 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| 11/19/2020 | Novartis Pharmaceuticals Corporation | TABRECTA (Drug) | Consulting Fee | Cash or cash equivalent | $4,375.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2020 | EMD Serono, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,760.00 | General |
| 08/06/2020 | Novartis Pharmaceuticals Corporation | INC280 (Drug) | — | In-kind items and services | $1,688.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 08/06/2020 | Novartis Pharmaceuticals Corporation | INC280 (Drug) | — | In-kind items and services | $713.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 07/31/2020 | Eli Lilly and Company | — | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE 1/2 STUDY OF LY3499446 ADMINISTERED TO PATIENTS WITH ADVANCED SOLID TUMORS WITH KRAS G12C MUTATION | ||||||
| 02/11/2020 | Novartis Pharmaceuticals Corporation | LXH254 (Drug) | — | In-kind items and services | $238.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 12/05/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $625.00 | General |
| 12/05/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | Cash or cash equivalent | $129.28 | General |
| 12/05/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $31.78 | General |
| 12/04/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $6,750.00 | General |
| 12/04/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | In-kind items and services | $385.11 | General |
| 12/04/2019 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Travel and Lodging | In-kind items and services | $129.27 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $2,639 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $992.11 | 1 |
| CJDQ443E12101 | Novartis Pharmaceuticals Corporation | $254.64 | 1 |
| ABI-007-NSCL-003 - A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction with nab-Paclitaxel Plus Carboplatin in su | Celgene Corporation | $193.63 | 1 |
| A PHASE 1/2 STUDY OF LY3499446 ADMINISTERED TO PATIENTS WITH ADVANCED SOLID TUMORS WITH KRAS G12C MUTATION | Eli Lilly and Company | $50.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 207 | 517 | $234,574 | $46,266 |
| 2022 | 5 | 218 | 551 | $255,079 | $52,232 |
| 2021 | 6 | 279 | 680 | $264,626 | $64,996 |
| 2020 | 7 | 312 | 653 | $197,196 | $44,893 |
Total Patients
1,016
Total Services
2,401
Medicare Billing
$208,387
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 60 | 168 | $104,268 | $20,172 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 88 | 234 | $94,927 | $18,588 | 19.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 85 | $26,610 | $5,694 | 21.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 17 | 19 | $5,299 | $1,052 | 19.9% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $3,470 | $759.55 | 21.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 73 | 185 | $113,663 | $22,882 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 89 | 264 | $105,277 | $21,650 | 20.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 39 | $15,891 | $3,401 | 21.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 18 | 43 | $12,260 | $2,607 | 21.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 20 | 20 | $7,988 | $1,692 | 21.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 85 | 237 | $116,929 | $29,796 | 25.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 93 | 247 | $84,640 | $20,797 | 24.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 27 | 81 | $23,727 | $5,037 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 21 | 46 | $19,460 | $4,112 | 21.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 32 | 44 | $14,468 | $3,781 | 26.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 21 | 25 | $5,402 | $1,472 | 27.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 100 | 312 | $99,726 | $21,537 | 21.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 67 | 127 | $60,930 | $12,175 | 20.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 36 | 51 | $8,141 | $3,587 | 44.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 50 | 62 | $7,715 | $2,820 | 36.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 41 | $11,931 | $2,617 | 21.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 30 | 36 | $7,529 | $1,624 | 21.6% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 15 | 24 | $1,224 | $533.78 | 43.6% |
About Rebecca Heist, MD MPH
Rebecca Heist, MD MPH is a Medical Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1184697278.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Rebecca Heist, MD MPH has received a total of $112,568 in payments from pharmaceutical and medical device companies, with $11,033 received in 2024. These payments were reported across 100 transactions from 17 companies. The most common payment nature is "Consulting Fee" ($95,663).
As a Medicare-enrolled provider, Heist has provided services to 1,016 Medicare beneficiaries, totaling 2,401 services with total Medicare billing of $208,387. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Internal Medicine
- Location Boston, MA
- Active Since 02/09/2006
- Last Updated 01/15/2026
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1184697278
Products in Payments
- TRADJENTA (Drug) $21,750
- TABRECTA (Drug) $9,150
- ILARIS (Biological) $7,570
- XALKORI (Drug) $6,540
- TAGRISSO (Drug) $3,477
- ONIVYDE (Drug) $2,500
- INC280 (Drug) $2,401
- ZYKADIA (Drug) $2,030
- ASB183X (Drug) $992.11
- Trodelvy (Drug) $760.00
- Alecensa (Biological) $577.18
- LXH254 (Drug) $238.00
- Abraxane (Drug) $193.63
- KEYTRUDA (Biological) $88.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Boston
Dr. George Demetri, Md, MD
Medical Oncology — Payments: $1.6M
Medical Oncology $1.6M
Pasi Antero Janne, Md Phd, MD PHD
Medical Oncology — Payments: $1.1M
Medical Oncology $1.1M
Dr. Praful Ravi, Mb Bchir, MB BCHIR
Medical Oncology — Payments: $921,658
Medical Oncology $921,658
Dr. Alicia Morgans, Md, MD
Medical Oncology — Payments: $755,277
Medical Oncology $755,277
Dr. Erica Mayer, Md Mph, MD MPH
Medical Oncology — Payments: $665,160
Medical Oncology $665,160
Dr. Joaquin Bellmunt Molins, M.d, M.D
Medical Oncology — Payments: $610,701
Medical Oncology $610,701